These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 34839814)

  • 1. Natalizumab administration in multiple sclerosis patients during active SARS-CoV-2 infection: a case series.
    Chisari CG; Toscano S; Arena S; Finocchiaro C; Montineri A; Patti F
    BMC Neurol; 2021 Nov; 21(1):462. PubMed ID: 34839814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of Natalizumab infusion in multiple sclerosis patients during active SARS-CoV-2 infection.
    Landi D; Cola G; Mantero V; Balgera R; Moiola L; Nozzolillo A; Dattola V; Sinisi L; Fantozzi R; Di Lemme S; Centonze D; Mataluni G; Nicoletti CG; Marfia GA
    Mult Scler Relat Disord; 2022 Jan; 57():103345. PubMed ID: 35158454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of disease-modifying treatments in SARS-CoV-2 antibody-positive multiple sclerosis patients.
    Mallucci G; Zito A; Baldanti F; Gastaldi M; Fabbro BD; Franciotta D; Bergamaschi R
    Mult Scler Relat Disord; 2021 Apr; 49():102754. PubMed ID: 33609958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical course and outcome of SARS-CoV-2 infection in multiple sclerosis patients treated with disease-modifying therapies - the Polish experience.
    Czarnowska A; Brola W; Zajkowska O; Rusek S; Adamczyk-Sowa M; Kubicka-Bączyk K; Kalinowska-Łyszczarz A; Kania K; Słowik A; Wnuk M; Marona M; Podlecka-Piętowska A; Nojszewska M; Zakrzewska-Pniewska B; Jasińska E; Gołuch K; Lech B; Noga M; Perenc A; Popiel M; Lasek-Bal A; Puz P; Maciejowska K; Kucharska-Lipowska M; Lipowski M; Kapica-Topczewska K; Chorąży M; Tarasiuk J; Kochanowicz J; Kulikowska J; Wawrzyniak S; Niezgodzińska-Maciejek A; Pokryszko-Dragan A; Gruszka E; Budrewicz S; Białek M; Kurkowska-Jastrzębska I; Kurowska K; Stępień A; Włodek A; Ptasznik V; Pawełczyk M; Sobolewski P; Lejmel H; Strzalińska K; Maciejowski M; Tutaj A; Zwiernik J; Litwin A; Lewańczyk B; Paprocka I; Zwiernik B; Pawlos A; Borysowicz A; Narożnik A; Michałowska A; Nosek K; Fudala M; Milewska-Jędrzejczak M; Kułakowska A; Bartosik-Psujek H
    Neurol Neurochir Pol; 2021; 55(2):212-222. PubMed ID: 33856686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study.
    Iaffaldano P; Lucisano G; Manni A; Paolicelli D; Patti F; Capobianco M; Brescia Morra V; Sola P; Pesci I; Lus G; De Luca G; Lugaresi A; Cavalla P; Montepietra S; Maniscalco GT; Granella F; Ragonese P; Vianello M; Brambilla L; Totaro R; Toscano S; Malucchi S; Petracca M; Moiola L; Ferraro D; Lepore V; Mosconi P; Ponzio M; Tedeschi G; Comi G; Battaglia MA; Filippi M; Amato MP; Trojano M;
    Neurol Neuroimmunol Neuroinflamm; 2022 Mar; 9(2):. PubMed ID: 35046084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unexpected worsening of progressive multifocal leucoencephalopathy following COVID-19 pneumonia.
    Borrelli S; Dachy B; Gazagnes MD; Du Pasquier R
    J Neurovirol; 2021 Jun; 27(3):510-513. PubMed ID: 33876412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 occurring during Natalizumab treatment: a case report in a patient with extended interval dosing approach.
    Borriello G; Ianniello A
    Mult Scler Relat Disord; 2020 Jun; 41():102165. PubMed ID: 32388451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of rebound effect after natalizumab withdrawal in multiple sclerosis. Study of two high-dose methylprednisolone schedules.
    Fuentes-Rumí L; Hernández-Clares R; Carreón-Guarnizo E; Valero-López G; Iniesta-Martinez F; Cabrera-Maqueda JM; León-Hernández A; Zamarro-Parra J; Morales-Ortiz A; Meca-Lallana JE
    Mult Scler Relat Disord; 2020 Sep; 44():102311. PubMed ID: 32593958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experiences in treatment of multiple sclerosis with natalizumab from a real-life cohort over 15 years.
    Auer M; Zinganell A; Hegen H; Bsteh G; Di Pauli F; Berek K; Fava E; Wurth S; Berger T; Deisenhammer F
    Sci Rep; 2021 Dec; 11(1):23317. PubMed ID: 34857795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COVID-19 in Argentine teriflunomide-treated multiple sclerosis patients: First national case series.
    Luetic G; Menichini ML; Burgos M; Alonso R; Carnero Contentti E; Carrá A; Deri N; Steinberg J; Rojas JI;
    Mult Scler Relat Disord; 2021 Aug; 53():103049. PubMed ID: 34130197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune-reconstitution Inflammatory Syndrome in Multiple Sclerosis Patients Treated With Natalizumab: A Series of 4 Cases.
    N'gbo N'gbo Ikazabo R; Mostosi C; Quivron B; Delberghe X; El Hafsi K; Lysandropoulos AP
    Clin Ther; 2016 Mar; 38(3):670-5. PubMed ID: 26856928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Catastrophic outcome of patients with a rebound after Natalizumab treatment discontinuation.
    González-Suarez I; Rodríguez de Antonio L; Orviz A; Moreno-García S; Valle-Arcos MD; Matias-Guiu JA; Valencia C; Jorquera Moya M; Oreja-Guevara C
    Brain Behav; 2017 Apr; 7(4):e00671. PubMed ID: 28413713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of autologous hematopoietic stem-cell transplantation following natalizumab discontinuation in aggressive multiple sclerosis.
    Mariottini A; Innocenti C; Forci B; Magnani E; Mechi C; Barilaro A; Nistri R; Fani A; Saccardi R; Massacesi L; Repice AM
    Eur J Neurol; 2019 Apr; 26(4):624-630. PubMed ID: 30414315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter, non-interventional study to evaluate the disease activity in Multiple Sclerosis after withdrawal of Natalizumab in Portugal.
    Ladeira F; Braz L; Salgado P; Vaz S; Leitão L; Félix C; Correia AS; Silva AMD; Salgado V; Ferreira F; Vale J; Sá MJ; Capela C
    Clin Neurol Neurosurg; 2019 Sep; 184():105390. PubMed ID: 31306895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of the COVID-19 pandemic on disease activity in multiple sclerosis patients treated with hematopoietic stem cell transplantation.
    Mariottini A; Lotti A; Innocenti C; Repice AM; Nozzoli C; Boncompagni R; Fainardi E; Saccardi R; Massacesi L
    Eur J Neurol; 2023 Oct; 30(10):3362-3366. PubMed ID: 37483174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.
    Safavi F; Nourbakhsh B; Azimi AR
    Mult Scler Relat Disord; 2020 Aug; 43():102195. PubMed ID: 32460086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alemtuzumab as rescue therapy in case of multiple sclerosis rebound following Natalizumab break: Clinical case and literature review.
    Federle L; Puthenparampil M; Stenta G; Paolo G; Francesco P
    Mult Scler Relat Disord; 2019 May; 30():262-264. PubMed ID: 30851640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for reactivation of clinical disease activity in multiple sclerosis after natalizumab cessation.
    Mustonen T; Rauma I; Hartikainen P; Krüger J; Niiranen M; Selander T; Simula S; Remes AM; Kuusisto H
    Mult Scler Relat Disord; 2020 Feb; 38():101498. PubMed ID: 31864192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Covid-19 in a patient with multiple sclerosis treated with natalizumab: May the blockade of integrins have a protective role?
    Aguirre C; Meca-Lallana V; Barrios-Blandino A; Del Río B; Vivancos J
    Mult Scler Relat Disord; 2020 Sep; 44():102250. PubMed ID: 32531754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natalizumab for relapsing remitting multiple sclerosis.
    Pucci E; Giuliani G; Solari A; Simi S; Minozzi S; Di Pietrantonj C; Galea I
    Cochrane Database Syst Rev; 2011 Oct; (10):CD007621. PubMed ID: 21975773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.